News & events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program.

3 July 2023

Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study

22 June 2023

Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress

30 March 2023

Invitation to investor meeting 5th April 2023, 2:00 pm (CET)

28 March 2023

Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer

8 March 2023

Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing its Expanded Clinical Portfolio Copy

23 January 2023

Events & Presentations

ESMO – 8-12 September 2017 Madrid

1 September 2017

ERS – 9-13 September 2017 Milan

1 September 2017

BIO USA – San Diego 19-22 June 2017

1 June 2017

ATS – Washington 19-24 May 2017

1 May 2017
This site is registered on as a development site.